Michael Michael1, Yung-Jue Bang2, Young Suk Park3, Yoon-Koo Kang4, Tae Min Kim5, Oday Hamid6, Donald Thornton6, Sonya C Tate7, Eyas Raddad6, Jeanne Tie8,9. 1. Division of Cancer Medicine, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. Michael.Michael@petermac.org. 2. Seoul National University College of Medicine, Seoul, South Korea. 3. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea. 4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 5. Seoul National University Hospital, Seoul, South Korea. 6. Eli Lilly and Company, Indianapolis, IN, USA. 7. Eli Lilly and Company, Basingstoke, Hampshire, UK. 8. Division of Cancer Medicine, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. 9. Royal Melbourne Hospital, Melbourne, Australia.
Abstract
BACKGROUND: We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor. OBJECTIVE: The primary objective was to determine the recommended phase 2 dosing (RP2D). Secondary objectives included determining toxicity, antitumor activity, pharmacokinetics (PK), and pharmacodynamic (PD) properties of LY2874455. PATIENTS AND METHODS: This study comprised two parts: (a) dose escalation with 3 + 3 cohorts in patients with solid tumors and (b) dose-expansion cohorts in patients with gastric cancer (GC) and non-small cell lung cancer (NSCLC). Part A: 36 patients in 11 dose cohorts ranging from 2 to 24 mg twice daily (BID). RP2D was 16 mg BID. Part B: GC cohort, 29 patients, NSCLC cohort, 27 patients, all treated at the RP2D. RESULTS: LY2874455 was slowly absorbed and generally showed linear PK. The effective half-life was ∼12 h. PD properties of LY2874455 occurred at doses ≥10 mg by increases in serum phosphorus. Phosphate binders were administered to control serum phosphorus. LY2874455 was generally well tolerated; most toxicities were grade 1 or 2; most frequent were hyperphosphatemia, diarrhea, and stomatitis. EFFICACY: part A: 24 patients evaluable: 1 patient in the 14-mg BID cohort with GC had a partial response (PR); 14 patients had stable disease (SD); part B: NSCLC cohort: 11 of 12 evaluable patients had SD; GC cohort: 15 patients evaluable: 1 patient with PR; 12 patients with SD. CONCLUSIONS: LY2874455 has an RP2D of 16 mg BID and demonstrated good tolerability and activity in solid-organ cancer patients. The role of FGFR inhibition on tumor growth in patients requires further study. (NCT01212107).
BACKGROUND: We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor. OBJECTIVE: The primary objective was to determine the recommended phase 2 dosing (RP2D). Secondary objectives included determining toxicity, antitumor activity, pharmacokinetics (PK), and pharmacodynamic (PD) properties of LY2874455. PATIENTS AND METHODS: This study comprised two parts: (a) dose escalation with 3 + 3 cohorts in patients with solid tumors and (b) dose-expansion cohorts in patients with gastric cancer (GC) and non-small cell lung cancer (NSCLC). Part A: 36 patients in 11 dose cohorts ranging from 2 to 24 mg twice daily (BID). RP2D was 16 mg BID. Part B: GC cohort, 29 patients, NSCLC cohort, 27 patients, all treated at the RP2D. RESULTS:LY2874455 was slowly absorbed and generally showed linear PK. The effective half-life was ∼12 h. PD properties of LY2874455 occurred at doses ≥10 mg by increases in serum phosphorus. Phosphate binders were administered to control serum phosphorus. LY2874455 was generally well tolerated; most toxicities were grade 1 or 2; most frequent were hyperphosphatemia, diarrhea, and stomatitis. EFFICACY: part A: 24 patients evaluable: 1 patient in the 14-mg BID cohort with GC had a partial response (PR); 14 patients had stable disease (SD); part B: NSCLC cohort: 11 of 12 evaluable patients had SD; GC cohort: 15 patients evaluable: 1 patient with PR; 12 patients with SD. CONCLUSIONS:LY2874455 has an RP2D of 16 mg BID and demonstrated good tolerability and activity in solid-organ cancerpatients. The role of FGFR inhibition on tumor growth in patients requires further study. (NCT01212107).
Authors: Gina M Yanochko; Allison Vitsky; Jonathan R Heyen; Brad Hirakawa; Justine L Lam; Jeff May; Tim Nichols; Frederick Sace; Dusko Trajkovic; Eileen Blasi Journal: Toxicol Sci Date: 2013-07-20 Impact factor: 4.849
Authors: Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Hans-Ulrich Schildhaus; Lukas C Heukamp; Sabine Merkelbach-Bruse; Katharina Riesner; Katja Schmitz; Elke Binot; Ellen Paggen; Kerstin Albus; Wolfgang Schulte; Yon-Dschun Ko; Andreas Schlesinger; Sascha Ansén; Walburga Engel-Riedel; Michael Brockmann; Monika Serke; Ulrich Gerigk; Sebastian Huss; Friederike Göke; Sven Perner; Khosro Hekmat; Konrad F Frank; Marcel Reiser; Roland Schnell; Marc Bos; Christian Mattonet; Martin Sos; Erich Stoelben; Jürgen Wolf; Thomas Zander; Reinhard Buettner Journal: Mod Pathol Date: 2012-06-08 Impact factor: 7.842
Authors: Melanie A Krook; Alexandria Lenyo; Max Wilberding; Hannah Barker; Mikayla Dantuono; Kelly M Bailey; Hui-Zi Chen; Julie W Reeser; Michele R Wing; Jharna Miya; Eric Samorodnitsky; Amy M Smith; Thuy Dao; Dorrelyn M Martin; Kristen K Ciombor; John Hays; Aharon G Freud; Sameek Roychowdhury Journal: Mol Cancer Ther Date: 2020-01-07 Impact factor: 6.261
Authors: Emilie M J van Brummelen; Evgeny Levchenko; Manuel Dómine; Dean A Fennell; Hedy L Kindler; Santiago Viteri; Shirish Gadgeel; Pilar Garrido López; Vladimir Kostorov; Daniel Morgensztern; Sergey Orlov; Marjorie G Zauderer; Johan F Vansteenkiste; Katherine Baker-Neblett; James Vasquez; Xiaowei Wang; David I Bellovin; Jan H M Schellens; Li Yan; Ionel Mitrica; M Phillip DeYoung; José Trigo Journal: Invest New Drugs Date: 2019-05-07 Impact factor: 3.850
Authors: Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga Journal: Clin Cancer Res Date: 2019-02-11 Impact factor: 13.801
Authors: Francesco Facchinetti; Antoine Hollebecque; Rastislav Bahleda; Yohann Loriot; Ken A Olaussen; Christophe Massard; Luc Friboulet Journal: Clin Cancer Res Date: 2019-10-04 Impact factor: 12.531